Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Conditions
- Prostatic Neoplasms
- Bone Density
Interventions
- DRUG: Zolderonic acid (Zometa)
Sponsor
Hospital Authority, Hong Kong
Collaborators